106PElevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer.
Annals of Oncology. 2019 Oct 1;30 (Supplement_5).
01/10/2019
dr. Christophe Ghysel
Urologie
» Contactgegevens op ziekenhuiswebsite